Who
Richard A. Heyman
Director
Company insider
Files Form 4 as: Director, Oric Pharmaceuticals; Director, Enliven Therapeutics; Director, PMV Pharmaceuticals; Director, RayzeBio; Director, Gritstone bio; Director, Metacrine; Director, Yumanity Therapeutics; Director, Receptos.
In numbers
- Trades disclosed
- 138
- Buys
- 0
- Sells
- 43
- Bought
- $0
- Sold
- $2.5M
- Companies
- 9
- Companies where not an officer
- 9
- First trade
- 21 Aug 2013
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $5,6003,500 at $1.60 | filing |
| 1 Oct 2026filed 2 Oct 2026 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $45K3,500 at $12.91 | filing |
| 1 Oct 2026filed 2 Oct 2026 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $41K3,200 at $12.91 | filing |
| 1 Oct 2026filed 2 Oct 2026 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 24 Jul 2026filed 28 Jul 2026 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $5,6003,500 at $1.60 | filing |
| 24 Jul 2026filed 28 Jul 2026 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $84K7,000 at $12.02 | filing |
| 24 Jul 2026filed 28 Jul 2026 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $73K6,100 at $12.02 | filing |
| 24 Jul 2026filed 28 Jul 2026 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 24 Jul 2026filed 28 Jul 2026 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 24 Jul 2026filed 28 Jul 2026 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $5,6003,500 at $1.60 | filing |
| 24 Jul 2026filed 28 Jul 2026 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $84K7,000 at $12.02 | filing |
| 24 Jul 2026filed 28 Jul 2026 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $73K6,100 at $12.02 | filing |
| 6 Jul 2026filed 8 Jul 2026 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3,600300 at $12.00 | filing |
| 6 Jul 2026filed 8 Jul 2026 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3,600300 at $12.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $32K1,230 at $26.18 | filing |
| 17 Feb 2026filed 19 Feb 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $32K1,230 at $26.18 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,234 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,234 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K512 at $26.46 | filing |
| 20 Jan 2026filed 22 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $19K718 at $26.96 | filing |
News
ORIC Pharmaceuticals Plans Phase 3 Trial For Enozertinib After Promising Lung Cancer DataORIC · rttnews.com · 23 Oct 2026Oric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 14,000 Shares of Company StockORIC · themarketsdaily.com · 22 Oct 2026Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst SaysELVN · dailypolitical.com · 21 Oct 2026Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearELVN · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name Richard A. Heyman; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.